^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Urothelial Cancer

    Related cancers:
    1d
    High Sensitivity ctDNA Analysis Using a Novel Panel and NOIR-SS Technology for Monitoring Advanced Urothelial Carcinoma. (PubMed, Cancer Med)
    Tumor tissue and serial plasma samples were collected from 15 patients with aUC treated with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC). While the NOIR-SS-based assay proved sensitive and informative, limitations include the cost and time required for sequencing, potential temporal discordance between tissue and plasma sampling, and the absence of correction for clonal hematopoiesis of indeterminate potential. Overall, ctDNA profiling using this targeted panel and NOIR-SS suggested the feasibility of sensitive, non-invasive molecular monitoring in aUC, and may have future clinical applicability if validated prospectively in larger cohorts.
    Journal • Circulating tumor DNA
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • FGFR3 mutation • HRAS mutation
    |
    cisplatin • doxorubicin hydrochloride • methotrexate • vinblastine
    1d
    RNDO-564-001: Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer (2025-524687-38-00)
    P1, N=34, Not yet recruiting, Rondo Therapeutics Inc.
    New P1 trial
    2d
    Filamin C activates MAPK/ERK signaling to facilitate epithelial-mesenchymal transition in bladder cancer. (PubMed, Clin Transl Oncol)
    FLNC drives BC progression and metastasis via MAPK/ERK activation and EMT induction.
    Journal
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • FLNC (Filamin C)
    3d
    KEYNOTE-D74: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 (clinicaltrials.gov)
    P3, N=412, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial primary completion date: Jun 2026 --> Jan 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Aidixi (disitamab vedotin)
    3d
    From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer. (PubMed, Front Immunol)
    Critically, most mechanistic findings remain at the preclinical or retrospective validation stage, with no markers yet approved for routine clinical use. Future work must prioritize longitudinal paired clinical samples, standardized analytic assays for dynamic biomarkers, and the integration of functional models (organoids, microfluidic systems), multi-omics technologies (single-cell sequencing, spatial transcriptomics), and liquid-biopsy approaches to translate mechanistic discoveries into clinically actionable predictive tools and therapeutic strategies.
    Review • Journal
    |
    JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • DDB1 (Damage Specific DNA Binding Protein 1) • HYAL4 (Hyaluronidase 4) • PHGDH (Phosphoglycerate Dehydrogenase) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • BECN1 (Beclin 1) • RAD54B (RAD54 Homolog B)
    |
    gemcitabine
    3d
    Detection of a group of classic serum tumor markers (CSTMs) aids in the differential diagnosis and disease assessment of upper tract urothelial carcinoma (UTUC). (PubMed, Transl Androl Urol)
    Group CSTM testing was shown to be more valuable than single CSTM testing. The recommended test strategy includes CA242, CA199, CEA, AFP, SCC, and CA724.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated) • AFP (Alpha-fetoprotein) • CA 19-9 (Cancer antigen 19-9)
    3d
    ALKBH2 promotes the Warburg effect and bladder cancer progression under hypoxic conditions via the PI3K/AKT pathway. (PubMed, Clin Exp Med)
    Mechanistic investigations revealed that ALKBH2 functions as an m6A demethylase to reduce PTEN mRNA stability, thereby activates the PI3K/AKT signaling pathway under hypoxic conditions, as evidenced by increased pathway activation, thereby facilitating metabolic reprogramming and tumor cell progression. These findings suggest that ALKBH2 plays a critical oncogenic role in bladder cancer by regulating PI3K/AKT pathway activation and promoting the Warburg effect, highlighting its potential as a therapeutic target for bladder cancer.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • ALKBH2 (AlkB Homolog 2)
    3d
    Refractory Diabetic Ketoacidosis Associated with Enfortumab Vedotin: A Pharmacokinetic-Based Management Approach. (PubMed, Kidney360)
    We describe a 57-year-old man receiving EV and pembrolizumab who developed profound insulin-resistant DKA that persisted despite standard therapy. Following initiation of induction alongside continued insulin therapy, resolution of ketoacidosis occurred within 46 hours. This case illustrates a pharmacokinetic-informed approach to EV-associated refractory DKA and highlights how understanding drug metabolism may improve therapeutic outcomes when conventional therapy is insufficient.
    PK/PD data • Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    4d
    Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis. (PubMed, Sci Rep)
    Grade-adapted interpretation is warranted. Prospective validation with standardised grade-specific reporting is needed.
    Retrospective data • Journal
    |
    Xpert® Bladder Cancer Monitor
    6d
    Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (clinicaltrials.gov)
    P3, N=654, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jul 2029 | Trial primary completion date: Jun 2026 --> Jul 2029
    Trial completion date • Trial primary completion date
    |
    IFNA1 (Interferon Alpha 1)
    |
    Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    7d
    NCI-2017-02296: Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ABL1 (ABL proto-oncogene 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • STK11 (Serine/threonine kinase 11) • NPM1 (Nucleophosmin 1) • POLE (DNA Polymerase Epsilon) • CCND1 (Cyclin D1) • BAP1 (BRCA1 Associated Protein 1) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • POLD1 (DNA Polymerase Delta 1) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • BRD4 (Bromodomain Containing 4) • DOT1L (DOT1 Like Histone Lysine Methyltransferase) • FANCE (FA Complementation Group E) • FANCG (FA Complementation Group G) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • FANCC (FA Complementation Group C)
    |
    PALB2 mutation • BRIP1 mutation
    |
    FoundationOne® CDx
    |
    Lynparza (olaparib)
    7d
    ETCTN 10183: Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Tazverik (tazemetostat)